Sware has secured $6m in a Series B funding round for expediting life sciences innovation by automating US Food and Drug Administration-mandated software validation.

The investment, led by First Analysis, will accelerate the development of Sware's Res_Q computer systems validation platform for streamlining processes with AI, and expand its sales team.

Sware has raised a total of $26m since its inception, with contributions from LRVHealth, New Stack Ventures, and Insight Partners.

Developed to address the challenges of validation debt in the life sciences sector, the Res_Q platform is designed to integrate and scale validation efforts across IT, manufacturing, and laboratory systems.

The cloud-based platform offers a comprehensive solution for medical device, pharmaceutical and biotechnology companies to automate, integrate and scale for managing their validation processes.

It features an open API architecture, as well as intelligent risk assessments to initiate workflows and assign workloads based on risk profiles.

Sware CEO Ellen Reilly said: “Every time a life sciences company adopts a new technology or every time technology vendors update products, validation requirements add time and unforeseen expenses that only compound as products move towards commercialisation. Automating these processes is the only way to eliminate this validation debt.

“We have deep experience helping life sciences companies through these processes and we’ve built everything we’ve learned into the Res_Q platform. This funding will enable us to scale the impact we’re making towards eliminating validation debt and to continue innovating with AI-driven capabilities for even smoother automation.”

First Analysis managing director Matt Nicklin will join the Sware board of directors as part of the investment agreement.